Biomarkers

A fragment of α-synuclein cleaved by Calpain-1, enabling non-invasive monitoring of neurodegenerative protein aggregation and neuronal injury.

A neo-epitope fragment of type I collagen generated by MMP activity, quantifying pathological soft tissue destruction and extracellular matrix turnover.

A neo-epitope fragment of type IV collagen generated by matrix metalloproteinase activity, enabling non-invasive assessment of basement membrane degradation and extracellular matrix remodeling in chronic inflammatory and fibrotic diseases.

A fragment of S100A9 (calprotectin) released by neutrophil elastase measured in blood, enabling precise assessment of active neutrophil-driven inflammation in systemic and tissue-specific conditions.

A neo-epitope fragment of biglycan generated by MMP-9 and MMP-12 activity, reflecting pericellular matrix degradation and extracellular matrix remodeling.

A fragment of glial fibrillary acidic protein cleaved by caspase-6, enabling non-invasive monitoring of astrocytic activation and central nervous system injury.

A fragment of neurocan cleaved by matrix metalloproteinase-2, enabling non-invasive monitoring of extracellular matrix remodeling and blood-brain barrier integrity in neurodegenerative conditions.

A structural axonal protein released upon neuronal damage, serving as a sensitive marker for neurodegeneration and axonal injury.

A fragment of nidogen-1 cleaved by cathepsin S, enabling non-invasive monitoring of basement membrane degradation and tumor microenvironment remodeling in cancer.

Blood-based detection of tau phosphorylated at threonine 217, enabling minimally invasive assessment of neurodegenerative pathology